Our findings should contribute to the improved performance of BC PRS for absolute risk prediction for BRCA1 and BRCA2 mutation carriers, which will help inform decisions on the best timing for risk-reducing surgery, risk reduction medication, or the start of surveillance. This evidence concerns the gene BRCA1 and breast cancer.